Search clinical trials for: Unresectable stage III Non-Small Cell lung Carcinoma

Total 126027 results

Xinqiao Hospital of Chongqing

Not yet recruiting

Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer

NSCLC | Radiotherapy | Immunotherapy | Intensity Modulated Radiation Therapy
AstraZeneca

Recruiting

CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC in Routine Practices in Russia (PASSAT)

Unresectable /Inoperable Locally Advanced (Stage II-III) Non-small Cells Lung Cancer (NSCLC)

Russian Federation
Biomea Fusion Inc.

Recruiting

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer

Colorectal Cancer | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | CRC | KRAS Mutation-Related Tumors | Relapsed Cancer | Refractory Cancer | Stage IV Non-small Cell Lung Cancer | Stage IV Colorectal Cancer | Stage III Non-small Cell Lung Cancer | Stage III NSCLC and other conditions

United States, Korea, Republic of
Fundación GECP

Recruiting

Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy (MERIT-lung)

Non-small Cell Lung Cancer Stage III | KRAS P.G12C

Spain
Iovance Biotherapeutics, Inc.

Recruiting

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer

Metastatic Melanoma | Unresectable Melanoma | Stage IV Non-small Cell Lung Cancer | Stage III Non-small Cell Lung Cancer

United States
Sung Yong Lee
Yuhan Corporation

Recruiting

A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy (PLATINUM)

Non-small Cell Lung Cancer Stage III | Non-squamous Non-small-cell Lung Cancer | EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
AstraZeneca

Recruiting

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC-9)

Non-Small Cell Lung Cancer

China, Australia, Korea, Republic of, Canada, Poland, Spain, Vietnam, Germany, Brazil, Italy, Japan, Taiwan, Thailand, United States, United Kingdom, Portugal, Turkey, France, Peru, Colombia, Russian Federation, Ukraine
AstraZeneca
Arcus Biosciences, Inc.

Recruiting

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC (PACIFIC-8)

Non-Small Cell Lung Cancer

Korea, Republic of, Philippines, United States, Belgium, Hungary, India, Norway, United Kingdom, France, Canada, Germany, Japan, Malaysia, Taiwan, Greece, Italy, Mexico, Turkey, South Africa, Chile, Brazil, Romania, Spain, Switzerland, ... and more
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Belgium, Canada, Australia, Brazil, China, Japan, Taiwan, Israel, France, Singapore, Germany, Italy, Spain, Thailand, Sweden, Turkey, Colombia, Costa Rica, Poland, Chile, United Kingdom, New Zealand, N... and more
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
First People's Hospital of Hangzhou

Not yet recruiting

Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer

Non-small Cell Lung Cancer Stage III

China
AstraZeneca

Completed

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United Kingdom, United States, Italy, Spain, France, Germany
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)

Non-small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, United Kingdom, Australia, Belgium, Brazil, Canada, China, Portugal, Spain, France, Germany, Poland, Hong Kong, Israel, Thailand, Turkey, Japan, Austria, Hungary, Italy, Taiwan, Netherlands, Greece, New... and more
AstraZeneca

Active, not recruiting

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA) (LAURA)

Non Small Cell Lung Cancer (Stage III)

United States, Spain, Taiwan, Thailand, Vietnam, Turkey, Korea, Republic of, Brazil, Hungary, India, Japan, Mexico, Peru, Russian Federation, China, Malaysia, Argentina
TheraOp
AstraZeneca

Active, not recruiting

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC (PACCELIO)

Stage III Non-small Cell Lung Cancer | Locally Advanced | Unresectable

Switzerland
Greg Durm, MD
Bristol-Myers Squibb; Big Ten Cancer Research Consortium

Active, not recruiting

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
BeiGene

Terminated

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China, Taiwan, Australia, United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Netherlands, Spain, Belgium, Brazil, Japan, China, Australia, Germany, Argentina, Canada, Czechia, France
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)

Completed

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

Lymphoma | Metastatic Melanoma | Metastatic Renal Cell Cancer | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm and other conditions

United States
Massachusetts General Hospital
Conquer Cancer Foundation

Active, not recruiting

Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer (UPLIFT)

Stage IV Non-Small Cell Lung Cancer | Stage IV Bladder Cancer | Stage IV Breast Cancer | Stage IV Melanoma | Immunotherapy | Immune Checkpoint Inhibitors | Stage IV Gastric Cancer | Stage IV Merkel Cell Carcinoma | Stage IV Colorectal Cancer | Stage IV Esophageal Cancer | Advanced Lung Cancer | Stage IV Renal... and other conditions

United States
Mario Negri Institute for Pharmacological Research
AstraZeneca; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Active, not recruiting

Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (BRIDGE)

Non-small Cell Lung Cancer Stage III

Italy, Spain, France
Groupe Français de Pneumo-Cancérologie
AstraZeneca

Active, not recruiting

Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE) (OBSTINATE)

Non-Small Cell Lung Cancer

France
AstraZeneca

Completed

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC)

Non-Small Cell Lung Cancer

United States, Belgium, France, Germany, Italy, Spain, Canada, Poland, Thailand, Vietnam, Korea, Republic of, Hungary, Japan, Mexico, Peru, Turkey, United Kingdom, Taiwan, Chile, Australia, Israel, South Africa, Netherlands, Greece, Sin... and more
Latin American Cooperative Oncology Group
AstraZeneca; Libbs Farmacêutica LTDA

Active, not recruiting

Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers (PACIFIC BRAZIL)

Lung Neoplasms

Brazil
AstraZeneca

Completed

Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom (CODAK)

Non-Small Cell Lung Cancer NSCLC

United Kingdom
AstraZeneca

Completed

RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada (RELEVANCE)

Non-small Cell Lung Cancer

Canada
University of Southern California
National Cancer Institute (NCI); Vasgene Therapeutics, Inc

Terminated

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Pancreatic Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage... and other conditions

United States
AstraZeneca

Terminated

Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab. (ON TRAX)

Unresectable Stage III NSCLC

United States
Jianguo Sun

Completed

Omitting Clinical Target Volume of Unresectable Stage III Non-small-cell Lung Cancer.

Stage III Non-small-cell Lung Cancer
Shandong Cancer Hospital and Institute

Terminated

A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Centre Leon Berard

Terminated

Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor (GFPC_01-14)

Non-small-cell Lung Carcinoma

France
H. Lee Moffitt Cancer Center and Research Institute
Nestle Health Science

Withdrawn

Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer

NSCLC | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | NSCLC Stage IIIB | Non-small Cell Lung Cancer Stage IIIB | NSCLC, Stage IIIA | Non-small Cell Lung Cancer Stage ⅢA

United States
Celgene
BeiGene

Terminated

A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer (RATIONALE001)

Carcinoma, Non-Small-Cell Lung

Spain, United States, Japan, China, Canada, United Kingdom, Belgium, Singapore, Korea, Republic of, Netherlands, France, Romania, Greece, Germany, Taiwan, Finland, Italy, Poland, Hungary, Ireland, Portugal, New Zealand, Russian Federation
Incyte Corporation

Withdrawn

INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)

Non-small Cell Lung Cancer
Incyte Corporation

Withdrawn

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Advanced and/or Metastatic Solid Tumors | Stage IIIB Not Amenable to Curative Therapy to Stage IV Non-small Cell Lung Cancer | Advanced/Metastatic Unresectable Malignant Pleural Mesothelioma
Cancer Institute and Hospital, Chinese Academy...

Unknown

Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC

Non Small Cell Lung Cancer | Stage III Non-small-cell Lung Cancer | EGFR Mutation-Related Tumors
Nanfang Hospital of Southern Medical University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer

Unresectable Stage III Non-small Cell Lung Cancer

China
Hoffmann-La Roche

Completed

Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China

Non-Small Cell Lung Cancer, Lung Cancer, Cancer

China
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Unresectable Malignant Neoplasm | Metastatic Neoplasm | Recurrent Neoplasm

United States
Shionogi

Completed

Study of S-3304 in Patients With Locally Advanced Non-Small Cell Lung Cancer

Lung Cancer | Non Small Cell Lung Cancer | Stage IIIA Non Small Cell Lung Cancer | Stage IIIB Non Small Cell Lung Cancer

United States
University of Turin, Italy

Unknown

Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC (MP-LALC)

Non Small Cell Lung Cancer Patients

Italy
Shanghai Chest Hospital

Unknown

Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC (HCFCCUSN)

Unresectable Stage III Non-small-cell Lung Cancer

China
Zhejiang Cancer Hospital
Fudan University; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC

Stage III Non-small-Cell Lung Cancer

China
Merck KGaA, Darmstadt, Germany

Withdrawn

Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer (FINGERPRINT)

Non-small Cell Lung Cancer (NSCLC) Stage III
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer

Lung Cancer

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)

Anorexia | Fatigue | Lung Cancer | Cachexia

United States
Merck KGaA, Darmstadt, Germany

Terminated

Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (INSPIRE)

Non-Small Cell Lung Cancer

Korea, Republic of, Taiwan, Singapore, China, Hong Kong
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
University of Southern California
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Recurrent Prostate Cancer | Stage III Renal Cell Cancer | Recurrent Endometrial Carcinoma | Male Breast Cancer | Stage IV Breast Cancer | Stage IV Ovarian Epithelial Cancer | Stage IV Ovarian Germ Cell Tumor | Stage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Stage IIIA Breast... and other conditions

United States

Search clinical trials for: Unresectable stage III Non-Small Cell lung Carcinoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations